Treatment by romosozumab in secondary osteoporosis: a review of the literature
Authors:
Brunerová Ludmila
Authors‘ workplace:
Interní klinika 3. LF UK a FNKV, Praha
Published in:
Clinical Osteology 2024; 29(1-2): 20-24
Category:
Overview
Osteoporosis represents the most common metabolic bone disease, which affects every third woman and every fifth man worldwide. Low-trauma fractures represent the most serious complications of osteoporosis, responsible for significant morbidity, mortality and increased economical costs. Therapy of osteoporosis is based on three pillars – lifestyle changes, suplementation of vitamin D and calcium and specific antiosteoporotic treatment, which is able to decrease the fracture risk in a half. Romosozumab, a humanized monoclonal antibody against sclerostin has been the most recent anabolic treatment introduced to the Czech market. I tis indicated and reimbursed in postmenopausal women with densitometry osteoporosis and with history of low-trauma fracture, who did not experienced myocardial infarction or stroke. In the following text, original data from studies, identified in PubMed and Medline Plus based on combinations of key words, focusing on the efficacy of romosozumab in specific clinical settings of secondary osteoporosis, is presented.
Keywords:
romosozumab – secondary osteoporosis
Sources
Kanis JA, Johnell O, Oden A et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11(8): 669–674. Dostupné z DOI: <http://dx.doi.org/10.1007/s001980070064>.
Riggs BL, Melton LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983; 75(6): 899–901. Dostupné z DOI: <http://dx.doi.org/10.1016/0002–9343(83)90860–4>.
Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 2015; 173(3): R131-R151. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-15–0118>..
Palička V, Rosa J, Pikner R et al. Doporučené diagnostické a terapeutické postupy pro praktické lékaře – Osteoporóza. Novelizace 2023. Dostupné z WWW: <https://smos.cz/wp-content/uploads/2023/12/doporucene_postupy_osteoporoza_2023.pdf>.
Brunerová L. Romosozumab. Zaostřeno. Remedia 2024; 34: 1–8.
Cosman F, Crittenden DB, Adachi JD et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375(16): 1532–1543. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607948>.
Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377(15): 1417–1427. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1708322>.
Langdahl BL, Libanati C, Crittenden DB et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 2017; 390(10102): 1585–1594. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)31613–6>.
Lewiecki EM, Blicharski T, Goemaere S et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab 2018; 103(9): 3183–3193. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2017–02163>.
Miller PD, Adachi JD, Albergaria BH et al. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res 2022; 37(8): 1437–1445. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.4563>.
Sato M, Inaba M, Yamada S et al. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 2021; 39(6): 1082–1090. Dostupné z DOI: <http://dx.doi.org/10.1007/s00774–021–01253-y>.
Ogata M, Ushimaru S, Fujishima R et al. Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist. Bone Rep 2022; 17:101639. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bonr.2022.101639>.
Hsu CP, Maddox J, Block G et al. Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab. J Clin Pharmacol 2022; 62(9): 1132–1141. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.2050>.
Mochizuki T, Yano K, Ikari K et al. Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia 2021; 7(3): 110–114. Dostupné z DOI: <http://dx.doi.org/10.1016/j.afos.2021.08.001>.
Mochizuki T, Yano K, Ikari K et al. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study. Mod Rheumatol 2023; 33(3): 490–495. Dostupné z DOI: <http://dx.doi.org/10.1093/mr/roac059>.
Ebina K, Nagayama Y, Kashii M et al. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study. Osteoporos Int 2024; 35(5): 841–849. Dostupné z DOI: <https://doi.org/10.1007/s00198–024–07019–2>.
Kurose R, Wakai Y. Efficacy of romosozumab for the treatment of osteoporosis in patients with rheumatoid arthritis in comparison with glucocorticoids therapy. Clin Rheumatol 2023; 35(3): 177–188. Dostupné z DOI: <https://doi.org/10.14961/cra.35.177>.
Kobayakawa T, Miyazaki A, Kanayama Y et al. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 2023; 33(1): 96–103. Dostupné z DOI: <https://doi.org/10.1093/mr/roac014>.
Mok CC, MD, Ma WH, Chan KL et al. Romosozumab versus denosumab in high-risk patients with glucocorticoid-induced osteoporosis: a pilot randomized controlled trial. Abstract OP0246. European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Meeting. Annals of the Rheumatic Diseases 2023; 82(Suppl 1):164.1–164
Kawazoe M, Kaneko K, Masuoka S et al. Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study. ACR Convergence 2023. Dostupné z WWW: <https://acrabstracts.org/abstract/efficacy-of-romosozumab-for-glucocorticoid-induced-osteoporosis-in-patients-with-rheumatic-diseases-a-prospective-study/>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2024 Issue 1-2
Most read in this issue
- System of coordinated care for osteoporotic patients in the Czech Republic
- Acetabuloplasty in therapy of severe dysplasia of the hip: case report
- Falls prevention – identification and intervention of risk factors
- Latest research and news in osteology